Elutia Inc. (ELUT) Stock Performance and Related Market Activity
Elutia Inc. (ticker: ELUT) closed 2.64 % higher during a 24‑hour period ending 09:56 PM Central Europe on Tuesday, 20 October 2026. The share price was approximately USD 0.81 on major exchanges.
- Shares Outstanding: 44.3 million
- Market Capitalisation: USD 35.2 million
- Volume (last 24 h): USD 50 k of shares traded
- Monthly Change: -4.45 % since the end of the previous month
- 200‑Day Simple Moving Average: USD 0.97
- 52‑Week High: USD 1.38 (4 March 2026)
- 52‑Week Low: USD 0.50 (17 December 2025)
Elutia is a biotechnology firm focused on developing proprietary drug‑eluting biologic technology for device implantation and soft‑tissue reconstruction. The company serves customers in the United States and is listed on the Nasdaq stock exchange. Its website is www.elutia.com .
Recent Performance of Related Stocks
| Ticker | Last 24‑hour Movement | Current Price (USD) | Market Capitalisation (USD) | Key Recent Developments |
|---|---|---|---|---|
| Elicio Therapeutics (9HA.F) | –12.36 % | 1.55 | 41 million | The KRAS inhibitor market is expanding; companies including Elicio are advancing therapies targeting G12C and G12D variants. Regulatory milestones such as breakthrough designations have accelerated approval pathways. |
| Comtech Telecommunications (CMTL) | –1.44 % | 1.34 | 41.9 million | The company achieved positive cash flow after a period of negative operating cash flow, indicating improved operational discipline. |
| Cable One (CABO) | –13.97 % | 6.20 | 41 million | An amendment to its Schedule 13D was filed on 20 October 2026, detailing the sale of over 5 % of common stock by Donald E. Graham and associated trusts. |
| Grove Collaborative (GROV) | +1.02 % | 0.99 | 41.9 million | No significant corporate actions reported in the last 24 hours. |
| Dogwood Therapeutics (DWTX) | –0.82 % | 1.17 | 41.5 million | The company announced a private placement of common stock with CK Life Sciences International, valued at approximately USD 5 million, to fund its Halneuron® Phase 2b program and Phase 3 preparations. |
These movements reflect broader sector trends and company‑specific events that may influence investor sentiment and valuation dynamics.
